∆Np73, TAp73 and ∆133p53 extracellular vesicle cargo as early diagnosis markers in colorectal cancer
EntityUAM. Departamento de Bioquímica
10.3390/cancers13092240Cancers 13.9 (2021): 2240
Funded byThis work was supported by PI18/00473 (ISCIII, Ministry of Economy and Competitiveness and co-funded with FEDER funds) and PI17CIII/00045 research project from AES-ISCIII.
ProjectGobierno de España. PI18/00473; Gobierno de España. PI17CIII/00045
Editor's Versionhttps://doi.org/10.3390/cancers 13092240
SubjectsBiomarkers; Colorectal cancer; Early diagnosis; Extracellular vesicles; Liquid biopsy; Premalignant lesions; Screening programs; TAp73; ∆133p53; ∆Np73; Biología y Biomedicina / Biología
Rights© 2021 by the authors
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
The early diagnosis of colorectal cancer is a key factor in the overall survival of the patients. The actual screening programs include different approaches with significant limitations such as unspecificity, high invasiveness, and detection at late stages of the disease. The specific content of extracellular vesicles derived from malignant cells may represent a non-invasive technique for the early detection of colorectal cancer. Here, we studied the mRNA levels of ∆Np73, TAp73, and ∆133p53 in plasma-derived extracellular vesicles from healthy subjects (n = 29), individuals with premalignant lesions (n = 49), and colorectal cancer patients (n = 42). Extracellular vesicles’ ∆Np73 levels were already significantly high in subjects with premalignant lesions. ∆133p53 levels were statistically increased in colorectal cancer patients compared to the other two groups and were associated with patients’ survival. Remarkably, TAp73 mRNA was not detected in any of the individuals. The evaluation of ∆Np73, ∆133p53 and CEA sensitivity, specificity and AUC values supports ∆Np73 as a better early diagnosis biomarker and CEA as the best to identify advanced stages. Thus, low levels of CEA and a high content of ∆Np73 may identify in screening programs those individuals at higher risk of presenting a premalignant lesion. In addition, ∆133p53 emerges as a potential prognosis biomarker in colorectal cancer
Google Scholar:Rodríguez-Cobos, Javier - Viñal, David - Poves, Carmen - Fernández-Aceñero, María J. - Peinado, Héctor - Pastor-Morate, Daniel - Prieto, Ma Isabel - Barderas, Rodrigo - Rodríguez Salas, Nuria - Domínguez Muñoz, Gemma
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform Garranzo-Asensio, María; Guzmán-Aránguez, Ana; Povedano, Eloy; Ruiz-Valdepeñas Montiel, Víctor; Poves, Carmen; Fernandez-Aceñero, María Jesús; Montero-Calle, Ana; Solís-Fernández, Guillermo; Fernandez-Diez, Servando; Camps, Jordi; Arenas, Meritxell; Rodríguez-Tomàs, Elisabeth; Joven, Jorge; Sanchez-Martinez, Maricruz; Rodríguez Salas, Nuria; Domínguez Muñoz, Gemma; Yáñez-Sedeño, Paloma; Pingarrón, José Manuel; Campuzano, Susana; Barderas, Rodrigo
The specifc seroreactivity to ∆Np73 isoforms shows higher diagnostic ability in colorectal cancer patients than the canonical p73 protein
Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients Herrera, Mercedes A.; Herrera, Alberto F.; Domínguez Muñoz, Gemma; Silva, Javier M.; García, Vanesa Quiroga; García, José Miguel Jurado; Gómez, Irene; Soldevilla, Beatriz; Muñoz, Concepción Morales; Provencio Pulla, Mariano; Campos-Martín, Yolanda; Garcia de Herreros, Antonio; Casal, Ignacio; Bonilla, Félix; Peña, Cristina